MicroPort Medical (0853.HK) Surges Over 8% on 200% YoY Growth in Coronary Stent Sales

MicroPort(00853) Rebounded significantly during the day, with the highest increase exceeding 9% in the afternoon. As of press time, MicroPort Medical rose by 8.47%, trading at HK$33.95, with a turnover of HK$220 million.

At the end of November, MicroPort (00853) held an investor teleconference. Regarding the latest business progress in the cardiovascular intervention product line, the company's executives stated that the sales volume of coronary stents, including Firebird2®, has achieved a year-on-year growth of 200%. Among this, revenue from overseas grew by 40-50%. MicroPort also indicated that the non-VBP product Firehawk® stent has seen significant volume expansion since the second half of this year. It has achieved local production in India and is undergoing large-scale clinical trials in the United States, with expectations to receive FDA approval as early as 2024.

Interim report data shows that in the first half of the year, MicroPort exceeded the sales target for the中标量 of coronary stents ahead of schedule.